Use of the pirfenidone for the infant with steroid-resistant chronic lung disease

Use of the pirfenidone for the infant with steroid-resistant chronic lung disease - Use of the pirfenidone for the infant with steroid-resistant chronic lung disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010194

Enrollment

Registered

2013-03-09

Start date

2013-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clonic lung disease, bronchopulmonary dysplasia

Interventions

pirfenidone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The bronchopulmonary dysplasia with low weight birth child, and home oxygen therapy, steroid, the administration of immunosuppressive drug, and is; the child who worsens respiratory status

Exclusion criteria

Exclusion criteria: The child who does not have taking pirfenidon

Design outcomes

Primary

Measure	Time frame
Improvement of the respiratory status Effect of reduction of steroid, the immunosuppressive drug check the side effect	—

Countries

Japan

Contacts

Public ContactHIdeki Motomura

Nagasaki University Hospital Pediatrics

hideki-m@nagasaki-u.ac.jp095-819-7298

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026